Outcomes after cessation of mepolizumab therapy in severe eosinophilic asthma: A 12-month follow-up analysis
A theoretical risk of "rebound" worsening of eosinophilic airway inflammation associated with negative outcomes has been suggested3 on the basis of in vitro observations that anti-IL-5 therapy is associated with upregulation of IL-5 synthesis by TH2 cells, upregulation of IL-5R expression...
Gespeichert in:
| Veröffentlicht in: | Journal of allergy and clinical immunology 2014-03, Vol.133 (3), p.921-923 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 923 |
|---|---|
| container_issue | 3 |
| container_start_page | 921 |
| container_title | Journal of allergy and clinical immunology |
| container_volume | 133 |
| creator | Haldar, Pranabashis, MD Brightling, Christopher E., PhD Singapuri, Amisha, BSc Hargadon, Beverley, BSc Gupta, Sumit, PhD Monteiro, William, BSc Bradding, Peter, PhD Green, Ruth H., MD Wardlaw, Andrew J., PhD Ortega, Hector, PhD Pavord, Ian D., DM |
| description | A theoretical risk of "rebound" worsening of eosinophilic airway inflammation associated with negative outcomes has been suggested3 on the basis of in vitro observations that anti-IL-5 therapy is associated with upregulation of IL-5 synthesis by TH2 cells, upregulation of IL-5R expression by eosinophils, and persistence of preformed IL-5 in complex with the drug for a variable period of time after cessation of therapy.4 As part of a follow-up analysis, subjects completing a 12-month study of mepolizumab in refractory asthma1 were observed for 12 months with assessments every 3 months. The rise in exacerbations at 3 to 6 months after stopping mepolizumab was preceded by a rise in sputum and blood eosinophils, supporting suggestions that these events are related but have different time courses.5-8 The finding of increased asthma symptoms following cessation of mepolizumab was unexpected because symptoms were not modified significantly during the treatment period.1 However, mean symptom scores for subjects receiving mepolizumab were lower than for subjects in the placebo group at the end of the treatment phase of the study. |
| doi_str_mv | 10.1016/j.jaci.2013.11.026 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1504162479</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0091674913018459</els_id><sourcerecordid>3556036141</sourcerecordid><originalsourceid>FETCH-LOGICAL-c535t-c4b22f0d8db4187e3f21d6f218dafe5b2bc9b33942a14a52b09113c2b9aa49e3</originalsourceid><addsrcrecordid>eNp9ktuKFDEQhoMo7jj6Al5IQARvesypTyLCsniChb1w70M6Xc2kTXfaVPfK7NPss_hkppnRhb3wJiHwVeX_6y9CXnK244wX7_pdb6zbCcbljvMdE8UjsuGsLrOiEvljsmGs5llRqvqMPEPsWXrLqn5KzoRSvFIV25DhapltGACp6WaI1AKimV0YaejoAFPw7nYZTEPnPUQzHagbKcINRKAQ0I1h2jvvLDU47wfznp7_vuMiG8I472kXvA-_smWiZjT-gA6fkyed8QgvTveWXH_-dH3xNbu8-vLt4vwys7nM58yqRoiOtVXbJJ0lyE7wtkhH1ZoO8kY0tm6krJUwXJlcNMknl1Y0tTGqBrklb49tpxh-LoCzHhxa8N6MEBbUPGeKF0KVdUJfP0D7sMQkN1GFUmWVV4onShwpGwNihE5P0Q0mHjRnes1C93rNQq9ZaM51yiIVvTq1XpoB2n8lf4efgDcnwKA1votmtA7vuUpWcjW2JR-OHKSR3TiIGq2D0ULrIthZt8H9X8fHB-XWu9GlH3_AAfDer0ahmf6-bs26NFyypDOv5R8NNL1y</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1644785841</pqid></control><display><type>article</type><title>Outcomes after cessation of mepolizumab therapy in severe eosinophilic asthma: A 12-month follow-up analysis</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>Haldar, Pranabashis, MD ; Brightling, Christopher E., PhD ; Singapuri, Amisha, BSc ; Hargadon, Beverley, BSc ; Gupta, Sumit, PhD ; Monteiro, William, BSc ; Bradding, Peter, PhD ; Green, Ruth H., MD ; Wardlaw, Andrew J., PhD ; Ortega, Hector, PhD ; Pavord, Ian D., DM</creator><creatorcontrib>Haldar, Pranabashis, MD ; Brightling, Christopher E., PhD ; Singapuri, Amisha, BSc ; Hargadon, Beverley, BSc ; Gupta, Sumit, PhD ; Monteiro, William, BSc ; Bradding, Peter, PhD ; Green, Ruth H., MD ; Wardlaw, Andrew J., PhD ; Ortega, Hector, PhD ; Pavord, Ian D., DM</creatorcontrib><description>A theoretical risk of "rebound" worsening of eosinophilic airway inflammation associated with negative outcomes has been suggested3 on the basis of in vitro observations that anti-IL-5 therapy is associated with upregulation of IL-5 synthesis by TH2 cells, upregulation of IL-5R expression by eosinophils, and persistence of preformed IL-5 in complex with the drug for a variable period of time after cessation of therapy.4 As part of a follow-up analysis, subjects completing a 12-month study of mepolizumab in refractory asthma1 were observed for 12 months with assessments every 3 months. The rise in exacerbations at 3 to 6 months after stopping mepolizumab was preceded by a rise in sputum and blood eosinophils, supporting suggestions that these events are related but have different time courses.5-8 The finding of increased asthma symptoms following cessation of mepolizumab was unexpected because symptoms were not modified significantly during the treatment period.1 However, mean symptom scores for subjects receiving mepolizumab were lower than for subjects in the placebo group at the end of the treatment phase of the study.</description><identifier>ISSN: 0091-6749</identifier><identifier>EISSN: 1097-6825</identifier><identifier>DOI: 10.1016/j.jaci.2013.11.026</identifier><identifier>PMID: 24418480</identifier><identifier>CODEN: JACIBY</identifier><language>eng</language><publisher>New York, NY: Elsevier Inc</publisher><subject>Allergy and Immunology ; Antibodies, Monoclonal, Humanized - therapeutic use ; Asthma - drug therapy ; Biological and medical sciences ; Clinical trials ; Follow-Up Studies ; Fundamental and applied biological sciences. Psychology ; Fundamental immunology ; Humans ; Immunopathology ; Interleukin-5 - antagonists & inhibitors ; Medical imaging ; Medical sciences ; Medical treatment ; Prospective Studies ; Pulmonary Eosinophilia - drug therapy ; Sarcoidosis. Granulomatous diseases of unproved etiology. Connective tissue diseases. Elastic tissue diseases. Vasculitis ; Treatment Outcome</subject><ispartof>Journal of allergy and clinical immunology, 2014-03, Vol.133 (3), p.921-923</ispartof><rights>American Academy of Allergy, Asthma & Immunology</rights><rights>2014 American Academy of Allergy, Asthma & Immunology</rights><rights>2015 INIST-CNRS</rights><rights>Copyright Elsevier Limited Mar 2014</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c535t-c4b22f0d8db4187e3f21d6f218dafe5b2bc9b33942a14a52b09113c2b9aa49e3</citedby><cites>FETCH-LOGICAL-c535t-c4b22f0d8db4187e3f21d6f218dafe5b2bc9b33942a14a52b09113c2b9aa49e3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.jaci.2013.11.026$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>315,782,786,3552,27931,27932,46002</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=28383911$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24418480$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Haldar, Pranabashis, MD</creatorcontrib><creatorcontrib>Brightling, Christopher E., PhD</creatorcontrib><creatorcontrib>Singapuri, Amisha, BSc</creatorcontrib><creatorcontrib>Hargadon, Beverley, BSc</creatorcontrib><creatorcontrib>Gupta, Sumit, PhD</creatorcontrib><creatorcontrib>Monteiro, William, BSc</creatorcontrib><creatorcontrib>Bradding, Peter, PhD</creatorcontrib><creatorcontrib>Green, Ruth H., MD</creatorcontrib><creatorcontrib>Wardlaw, Andrew J., PhD</creatorcontrib><creatorcontrib>Ortega, Hector, PhD</creatorcontrib><creatorcontrib>Pavord, Ian D., DM</creatorcontrib><title>Outcomes after cessation of mepolizumab therapy in severe eosinophilic asthma: A 12-month follow-up analysis</title><title>Journal of allergy and clinical immunology</title><addtitle>J Allergy Clin Immunol</addtitle><description>A theoretical risk of "rebound" worsening of eosinophilic airway inflammation associated with negative outcomes has been suggested3 on the basis of in vitro observations that anti-IL-5 therapy is associated with upregulation of IL-5 synthesis by TH2 cells, upregulation of IL-5R expression by eosinophils, and persistence of preformed IL-5 in complex with the drug for a variable period of time after cessation of therapy.4 As part of a follow-up analysis, subjects completing a 12-month study of mepolizumab in refractory asthma1 were observed for 12 months with assessments every 3 months. The rise in exacerbations at 3 to 6 months after stopping mepolizumab was preceded by a rise in sputum and blood eosinophils, supporting suggestions that these events are related but have different time courses.5-8 The finding of increased asthma symptoms following cessation of mepolizumab was unexpected because symptoms were not modified significantly during the treatment period.1 However, mean symptom scores for subjects receiving mepolizumab were lower than for subjects in the placebo group at the end of the treatment phase of the study.</description><subject>Allergy and Immunology</subject><subject>Antibodies, Monoclonal, Humanized - therapeutic use</subject><subject>Asthma - drug therapy</subject><subject>Biological and medical sciences</subject><subject>Clinical trials</subject><subject>Follow-Up Studies</subject><subject>Fundamental and applied biological sciences. Psychology</subject><subject>Fundamental immunology</subject><subject>Humans</subject><subject>Immunopathology</subject><subject>Interleukin-5 - antagonists & inhibitors</subject><subject>Medical imaging</subject><subject>Medical sciences</subject><subject>Medical treatment</subject><subject>Prospective Studies</subject><subject>Pulmonary Eosinophilia - drug therapy</subject><subject>Sarcoidosis. Granulomatous diseases of unproved etiology. Connective tissue diseases. Elastic tissue diseases. Vasculitis</subject><subject>Treatment Outcome</subject><issn>0091-6749</issn><issn>1097-6825</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9ktuKFDEQhoMo7jj6Al5IQARvesypTyLCsniChb1w70M6Xc2kTXfaVPfK7NPss_hkppnRhb3wJiHwVeX_6y9CXnK244wX7_pdb6zbCcbljvMdE8UjsuGsLrOiEvljsmGs5llRqvqMPEPsWXrLqn5KzoRSvFIV25DhapltGACp6WaI1AKimV0YaejoAFPw7nYZTEPnPUQzHagbKcINRKAQ0I1h2jvvLDU47wfznp7_vuMiG8I472kXvA-_smWiZjT-gA6fkyed8QgvTveWXH_-dH3xNbu8-vLt4vwys7nM58yqRoiOtVXbJJ0lyE7wtkhH1ZoO8kY0tm6krJUwXJlcNMknl1Y0tTGqBrklb49tpxh-LoCzHhxa8N6MEBbUPGeKF0KVdUJfP0D7sMQkN1GFUmWVV4onShwpGwNihE5P0Q0mHjRnes1C93rNQq9ZaM51yiIVvTq1XpoB2n8lf4efgDcnwKA1votmtA7vuUpWcjW2JR-OHKSR3TiIGq2D0ULrIthZt8H9X8fHB-XWu9GlH3_AAfDer0ahmf6-bs26NFyypDOv5R8NNL1y</recordid><startdate>20140301</startdate><enddate>20140301</enddate><creator>Haldar, Pranabashis, MD</creator><creator>Brightling, Christopher E., PhD</creator><creator>Singapuri, Amisha, BSc</creator><creator>Hargadon, Beverley, BSc</creator><creator>Gupta, Sumit, PhD</creator><creator>Monteiro, William, BSc</creator><creator>Bradding, Peter, PhD</creator><creator>Green, Ruth H., MD</creator><creator>Wardlaw, Andrew J., PhD</creator><creator>Ortega, Hector, PhD</creator><creator>Pavord, Ian D., DM</creator><general>Elsevier Inc</general><general>Elsevier</general><general>Elsevier Limited</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7SS</scope><scope>7T5</scope><scope>H94</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>7X8</scope></search><sort><creationdate>20140301</creationdate><title>Outcomes after cessation of mepolizumab therapy in severe eosinophilic asthma: A 12-month follow-up analysis</title><author>Haldar, Pranabashis, MD ; Brightling, Christopher E., PhD ; Singapuri, Amisha, BSc ; Hargadon, Beverley, BSc ; Gupta, Sumit, PhD ; Monteiro, William, BSc ; Bradding, Peter, PhD ; Green, Ruth H., MD ; Wardlaw, Andrew J., PhD ; Ortega, Hector, PhD ; Pavord, Ian D., DM</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c535t-c4b22f0d8db4187e3f21d6f218dafe5b2bc9b33942a14a52b09113c2b9aa49e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Allergy and Immunology</topic><topic>Antibodies, Monoclonal, Humanized - therapeutic use</topic><topic>Asthma - drug therapy</topic><topic>Biological and medical sciences</topic><topic>Clinical trials</topic><topic>Follow-Up Studies</topic><topic>Fundamental and applied biological sciences. Psychology</topic><topic>Fundamental immunology</topic><topic>Humans</topic><topic>Immunopathology</topic><topic>Interleukin-5 - antagonists & inhibitors</topic><topic>Medical imaging</topic><topic>Medical sciences</topic><topic>Medical treatment</topic><topic>Prospective Studies</topic><topic>Pulmonary Eosinophilia - drug therapy</topic><topic>Sarcoidosis. Granulomatous diseases of unproved etiology. Connective tissue diseases. Elastic tissue diseases. Vasculitis</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Haldar, Pranabashis, MD</creatorcontrib><creatorcontrib>Brightling, Christopher E., PhD</creatorcontrib><creatorcontrib>Singapuri, Amisha, BSc</creatorcontrib><creatorcontrib>Hargadon, Beverley, BSc</creatorcontrib><creatorcontrib>Gupta, Sumit, PhD</creatorcontrib><creatorcontrib>Monteiro, William, BSc</creatorcontrib><creatorcontrib>Bradding, Peter, PhD</creatorcontrib><creatorcontrib>Green, Ruth H., MD</creatorcontrib><creatorcontrib>Wardlaw, Andrew J., PhD</creatorcontrib><creatorcontrib>Ortega, Hector, PhD</creatorcontrib><creatorcontrib>Pavord, Ian D., DM</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Entomology Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of allergy and clinical immunology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Haldar, Pranabashis, MD</au><au>Brightling, Christopher E., PhD</au><au>Singapuri, Amisha, BSc</au><au>Hargadon, Beverley, BSc</au><au>Gupta, Sumit, PhD</au><au>Monteiro, William, BSc</au><au>Bradding, Peter, PhD</au><au>Green, Ruth H., MD</au><au>Wardlaw, Andrew J., PhD</au><au>Ortega, Hector, PhD</au><au>Pavord, Ian D., DM</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Outcomes after cessation of mepolizumab therapy in severe eosinophilic asthma: A 12-month follow-up analysis</atitle><jtitle>Journal of allergy and clinical immunology</jtitle><addtitle>J Allergy Clin Immunol</addtitle><date>2014-03-01</date><risdate>2014</risdate><volume>133</volume><issue>3</issue><spage>921</spage><epage>923</epage><pages>921-923</pages><issn>0091-6749</issn><eissn>1097-6825</eissn><coden>JACIBY</coden><abstract>A theoretical risk of "rebound" worsening of eosinophilic airway inflammation associated with negative outcomes has been suggested3 on the basis of in vitro observations that anti-IL-5 therapy is associated with upregulation of IL-5 synthesis by TH2 cells, upregulation of IL-5R expression by eosinophils, and persistence of preformed IL-5 in complex with the drug for a variable period of time after cessation of therapy.4 As part of a follow-up analysis, subjects completing a 12-month study of mepolizumab in refractory asthma1 were observed for 12 months with assessments every 3 months. The rise in exacerbations at 3 to 6 months after stopping mepolizumab was preceded by a rise in sputum and blood eosinophils, supporting suggestions that these events are related but have different time courses.5-8 The finding of increased asthma symptoms following cessation of mepolizumab was unexpected because symptoms were not modified significantly during the treatment period.1 However, mean symptom scores for subjects receiving mepolizumab were lower than for subjects in the placebo group at the end of the treatment phase of the study.</abstract><cop>New York, NY</cop><pub>Elsevier Inc</pub><pmid>24418480</pmid><doi>10.1016/j.jaci.2013.11.026</doi><tpages>3</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0091-6749 |
| ispartof | Journal of allergy and clinical immunology, 2014-03, Vol.133 (3), p.921-923 |
| issn | 0091-6749 1097-6825 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1504162479 |
| source | MEDLINE; Elsevier ScienceDirect Journals Complete; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals |
| subjects | Allergy and Immunology Antibodies, Monoclonal, Humanized - therapeutic use Asthma - drug therapy Biological and medical sciences Clinical trials Follow-Up Studies Fundamental and applied biological sciences. Psychology Fundamental immunology Humans Immunopathology Interleukin-5 - antagonists & inhibitors Medical imaging Medical sciences Medical treatment Prospective Studies Pulmonary Eosinophilia - drug therapy Sarcoidosis. Granulomatous diseases of unproved etiology. Connective tissue diseases. Elastic tissue diseases. Vasculitis Treatment Outcome |
| title | Outcomes after cessation of mepolizumab therapy in severe eosinophilic asthma: A 12-month follow-up analysis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-05T01%3A01%3A54IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Outcomes%20after%20cessation%20of%20mepolizumab%20therapy%20in%20severe%20eosinophilic%20asthma:%20A%C2%A012-month%20follow-up%20analysis&rft.jtitle=Journal%20of%20allergy%20and%20clinical%20immunology&rft.au=Haldar,%20Pranabashis,%20MD&rft.date=2014-03-01&rft.volume=133&rft.issue=3&rft.spage=921&rft.epage=923&rft.pages=921-923&rft.issn=0091-6749&rft.eissn=1097-6825&rft.coden=JACIBY&rft_id=info:doi/10.1016/j.jaci.2013.11.026&rft_dat=%3Cproquest_cross%3E3556036141%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1644785841&rft_id=info:pmid/24418480&rft_els_id=S0091674913018459&rfr_iscdi=true |